Syndrome de Wiskott-Aldrich

Overview

Syndrome de Wiskott-Aldrich (WAS) est un trouble rare et héréditaire lié au chromosome X causé par des variants délétères dans le gène WAS. Il affecte principalement les hommes et perturbe la fonction des cellules immunitaires et des plaquettes, les composants sanguins qui aident à arrêter les saignements. La forme classique provoque des plaquettes anormalement petites et peu nombreuses, des saignements et des ecchymoses, de l’eczéma, des infections récurrentes ou graves, une maladie auto-immune et un risque accru de lymphome et d’autres cancers. La gravité varie considérablement, mais le WAS classique non traité peut être grave, voire mettre la vie en danger. WAS-Related Disorders (ncbi.nlm.nih.gov)

Definitive treatment has traditionally been an allogeneic hematopoietic stem-cell transplant (HSCT), in which blood-forming stem cells from a donor replace the patient’s defective immune and blood system. Supportive care can include immunoglobulin replacement, infection prevention and treatment, skin care, platelet-focused bleeding management, and treatment of autoimmune complications. In the United States, autologous gene therapy with etuvetidigene autotemcel (Waskyra) is now also an approved definitive option for eligible patients without a suitable HLA-matched related donor. WAS-Related Disorders FDA approval announcement (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has moved WAS from an experimental gene-therapy success story toward regulated clinical practice. The dominant questions are now how durably lentiviral gene therapy corrects immune dysfunction and bleeding, how to improve platelet recovery and autoimmune control, how to monitor lifelong risks from integrating vectors and conditioning chemotherapy, and whether precision gene editing can restore normal WAS expression more completely. The field is relatively advanced for an ultra-rare disease: a first gene therapy was approved by the FDA on December 9, 2025, while gene-editing approaches remain preclinical. FDA approval announcement Targeted gene correction in HSPCs (fda.gov)

Major Breakthroughs and Emerging Therapies

La percée centrale est la thérapie génique par lentiviral des cellules souches hématopoïétiques, désormais représentée par etuvetidigene autotemcel (etu-cel; Waskyra, précédemment OTL-103). Les médecins prélevent les propres cellules souches et progénitrices hématopoïétiques CD34-positives du patient, ajoutent une copie fonctionnelle de l’ADN complémentaire WAS en dehors du corps avec un vecteur lentiviral auto-inactivant, administrent une chimiothérapie de conditionnement pour libérer l’espace médullaire et réinfusent les cellules corrigées chez le patient. Dans l’analyse clinique regroupée de 27 participants, la survie globale était de 96 % à un et à cinq ans; les taux d’infection sévère sont passés de 2,00 à 0,15 événements par personne-année, et les saignements modérés ou graves sont passés de 2,00 à 0,80 événements par personne-année. Aucune oncogenèse par insertion n’a été observée au cours du suivi rapporté. Etuvetidigene autotemcel trial (nejm.org)

This evidence supported FDA approval of Waskyra on December 9, 2025 for patients aged six months and older with a pathogenic WAS variant, when HSCT is appropriate but no suitable HLA-matched related donor is available. This is an important practical distinction: etu-cel is not simply symptom control but a one-time treatment intended to establish a long-lasting population of genetically corrected blood-forming cells. FDA approval announcement Waskyra regulatory summary (fda.gov)

Other recent long-term lentiviral results reinforce the durability of this strategy. A 2022 follow-up of eight patients treated in French and United Kingdom phase 1/2 programs reported a median 7.6 years of follow-up, stable engraftment of corrected cells, no serious treatment-associated adverse events, resolution or marked improvement of severe infections and eczema, and fewer autoimmune and bleeding events. However, platelet counts often remained below normal, showing that clinical protection from bleeding can improve even when full platelet correction is not achieved. Long-term lentiviral gene therapy follow-up (nature.com)

Gene editing is the most important emerging alternative. In a 2020 preclinical study, CRISPR-Cas9 editing precisely corrected WAS in up to 60% of human hematopoietic stem and progenitor cells, restored WAS protein expression and immune-cell function, and showed persistence of edited long-term repopulating cells after transplantation into immunodeficient mice. Targeted gene correction in HSPCs (pubmed.ncbi.nlm.nih.gov) More recently, patient-derived induced pluripotent stem-cell models showed that direct mutation correction restored normal WAS protein levels in megakaryocytes, the platelet-producing cells, and improved proplatelet formation and platelet size more effectively than insertion of a transgene at a “safe-harbor” site. These findings support the hypothesis that precisely restoring normal gene regulation may better address the persistent platelet problem, but this approach has not yet entered clinical trials. Gene correction in WAS iPS cells (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The pivotal development program for etu-cel combined an eight-participant phase 1/2 study, a 10-participant phase 3 study, and nine patients treated through expanded access. The phase 3 cryopreserved-product study, NCT03837483, is sponsored by Fondazione Telethon and remains listed as active but not recruiting; it enrolled 10 participants, reached primary completion on March 18, 2024, and has estimated study completion in September 2027. Etuvetidigene autotemcel trial NCT03837483 trial record (nejm.org)

A separate U.S. phase 1/2 study, NCT01410825, reported outcomes in five patients receiving a self-inactivating lentiviral vector after busulfan and fludarabine conditioning. At a median 7.6 years of follow-up, all participants were alive and well, with sustained gene marking and improvement in eczema, infections, bleeding tendency, and immune function. Autoimmune flares occurred transiently in two patients who had pre-existing autoimmunity, highlighting an important clinical subgroup for continued study. U.S. phase 1/2 gene-therapy outcomes (pubmed.ncbi.nlm.nih.gov)

Long-term follow-up is now itself a major experimental and regulatory activity. The FDA required a prospective 15-year post-marketing observational study of 14 etu-cel recipients to assess secondary malignancies and long-term safety, with planned study completion on June 30, 2046. Waskyra approval letter (fda.gov)

Methodologies and Scientific Approaches

Current curative research is centered on ex vivo correction of autologous hematopoietic stem and progenitor cells. Researchers measure whether corrected cells engraft across blood lineages, quantify vector copy number, assess WAS protein expression by flow cytometry, monitor T-cell and B-cell recovery, track infection and bleeding rates, and map lentiviral integration sites to detect abnormal clonal expansion or possible cancer risk. Long-term lentiviral gene therapy follow-up (nature.com)

Investigators are also comparing cell sources and disease models to improve the therapy. An exploratory study in 13 pediatric recipients found that mobilized peripheral-blood stem cells and bone-marrow stem cells could both be gene-corrected and persist, but mobilized peripheral-blood products were associated with faster neutrophil and platelet recovery and greater myeloid gene correction. Patient-derived induced pluripotent stem cells, immunodeficient mouse transplants, and detailed platelet-production assays are being used to test whether gene editing can overcome incomplete platelet correction. Hematopoietic reconstitution after gene therapy Gene correction in WAS iPS cells (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Fondazione Telethon is the sponsor and U.S. biologics-license applicant for Waskyra, while the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan developed the underlying program. The pivotal clinical work involved SR-Tiget and IRCCS San Raffaele Scientific Institute in Italy, Children’s Healthcare of Atlanta in the United States, and manufacturing support from AGC Biologics; the pivotal publication reports funding from Fondazione Telethon and other contributors. Etuvetidigene autotemcel trial Waskyra product page (nejm.org)

Additional important research groups include the U.S. multicenter team reporting long-term phase 1/2 outcomes, and the Chulalongkorn University–King Chulalongkorn Memorial Hospital collaboration in Thailand, which has developed patient-derived stem-cell and platelet-production models for direct gene-correction research. Rather than relying on a single disease-specific grant, the field has advanced through foundation-sponsored translational programs, academic clinical centers, and regulatory incentives including orphan-drug, rare-pediatric-disease, and regenerative-medicine advanced-therapy designations for Waskyra. U.S. phase 1/2 gene-therapy outcomes Gene correction in WAS iPS cells Waskyra regulatory summary (pubmed.ncbi.nlm.nih.gov)

Strengths, Limitations, and Challenges

The strongest evidence supports lentiviral autologous stem-cell gene therapy as a durable, one-time disease-modifying treatment that avoids donor-cell graft-versus-host disease and can be used when a suitably matched related donor is unavailable. Clinical studies show major reductions in infections, eczema, and serious bleeding, with sustained multilineage engraftment and no reported insertional cancers in the published etu-cel analysis. Etuvetidigene autotemcel trial U.S. phase 1/2 gene-therapy outcomes (nejm.org)

Important limitations remain. Patients must still undergo chemotherapy conditioning, which contributes risks including febrile neutropenia, infections, liver injury, infertility risk, and other toxicities. Platelet counts may remain below normal, autoimmune disease can recur or flare, and the long-term risk of secondary malignancy from integrating-vector therapy cannot yet be considered fully resolved; these concerns explain the FDA’s mandatory 15-year follow-up requirement. Because treatment requires personalized cell collection, genetic modification, specialized transplantation care, and long-term monitoring, access and manufacturing capacity will remain practical barriers even after approval. Waskyra regulatory summary Long-term lentiviral gene therapy follow-up (fda.gov)

Outlook and Future Directions

WAS est plus proche d’une guérison fonctionnelle que jamais auparavant : les patients éligibles aux États‑Unis ont désormais accès à une thérapie génique autologue approuvée par la FDA, avec des preuves pluriannuelles d’un bénéfice clinique soutenu. Les prochains jalons sont un accès plus large au Waskyra dans le monde réel, la publication de suites d’essais de phase 3 plus longues et d’un suivi post-commercialisation, des preuves plus claires sur la fertilité et le risque de cancer après le conditionnement et l’intégration lentivirale, et la traduction clinique des stratégies d’édition génétique conçues pour restaurer une expression de la protéine WAS plus physiologique — en particulier dans les cellules productrices de plaquettes. La conclusion honnête à court terme est que la thérapie génique lentivirale est désormais une thérapie définitive cliniquement disponible pour des patients sélectionnés, tandis qu’un remède par édition génétique plus sûr ou plus complet demeure un objectif important mais préclinique. FDA approval announcement Waskyra approval letter Targeted gene correction in HSPCs (fda.gov)

References

• WAS-Related Disorders — GeneReviews®, 2025.
• FDA approval announcement — U.S. Food and Drug Administration, 2025.
• Waskyra product page — U.S. Food and Drug Administration, 2025.
• Waskyra regulatory summary — U.S. Food and Drug Administration, 2025.
• Waskyra approval letter — U.S. Food and Drug Administration, 2025.
• Etuvetidigene autotemcel trial — Ferrua et al., New England Journal of Medicine, 2026.
• NCT03837483 trial record — ClinicalTrials.gov, 2025.
• Long-term lentiviral gene therapy follow-up — Labrosse et al., Nature Medicine, 2022.
• U.S. phase 1/2 gene-therapy outcomes — Labrosse et al., Blood, 2023.
• Hematopoietic reconstitution after gene therapy — Pellin et al., Nature Medicine, 2023.
• Targeted gene correction in HSPCs — Rai et al., Nature Communications, 2020.
• Gene correction in WAS iPS cells — Ingrungruanglert et al., Thrombosis and Haemostasis, 2025.